Myeloma Clinical Trial
Official title:
Long-Term Observational Follow-Up Study of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (240 MCG/KG) Plus G-CSF (10 MCG/KG) Versus G-CSF (10 MCG/KG) Plus Placebo to Mobilize and Collect >/= 6 x 10^6 CD34+ Cells/KG in Multiple Myeloma Patients for Autologous Transplantation
Objectives:
The objective of this long-term observational study is to assess progression-free survival
and overall survival for a period of five years following the first dose of study treatment
(placebo or plerixafor [AMD3100]) in protocol AMD3100-3102. Patients that received at least
1 dose of study treatment (placebo or plerixafor) in the multicenter, randomized,
double-blind, placebo-controlled AMD3100-3102 study, which was designed to evaluate
plerixafor plus granulocyte colony stimulating factor (G-CSF) versus placebo plus G-CSF to
mobilize hematopoietic stem cells for autologous transplantation of Multiple Myeloma (MM)
patients are eligible.
Informed Consent Process:
Your study doctor or staff will either meet with you in person or contact you by phone to
review the study information. You will be given a copy of this consent form to review and
ask questions.
If you agree to take part in this study, you should sign this consent form on the date that
you agree to be in the study. If you agree to take part during a phone call with a member of
the study team, you should sign and date the form right away, on the date of the phone call,
and mail the form to the study doctor or staff. Please keep a copy for your own reference.
5-Year Follow-Up: You will be contacted by phone or in person at a visit, every 6 months for
5 years from the time of your first study drug/placebo dose in the 2004-0982 study. A
placebo is a substance that looks like the study drug but has no active ingredients.
If you received a transplant in the 2004-0982 study, your first contact in this study will
either be about 18 months from the time you began the 2004-0982 study, or at the time you
sign this consent form.
If you did not receive a transplant, your first contact in this study will be at the time
you sign this consent form.
At your first visit or call, you will be asked about the status of the disease, any changes
in the multiple myeloma that may have occurred since the 2004-0982 study, and any additional
treatments you may have received during that time.
At every visit or call after that, you will be asked about the status of the multiple
myeloma, any changes in the disease, and any treatments you have received since the last
visit or call. These questionnaires will take about 10 minutes each time.
Your doctor or the study staff also may contact your local doctor in order to collect
information from your medical records or for information about your medical history and
disease status.
Length of Study Participation:
You will be off study after your last study phone call or visit (about 5 years after your
first study drug/placebo dose in the 2004-0982 study).
This is an investigational study. Up to 300 patients will participate in this multi-center
study. Up to 12 will be enrolled at MD Anderson.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03832127 -
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients
|
Phase 1 | |
Completed |
NCT01413178 -
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
|
Phase 3 | |
Recruiting |
NCT03641456 -
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
|
Phase 2 | |
Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
Completed |
NCT03135925 -
Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation
|
N/A | |
Withdrawn |
NCT02114502 -
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
|
Phase 2 | |
Completed |
NCT00794261 -
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma
|
Phase 2 | |
Completed |
NCT00800839 -
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
|
Phase 2 | |
Completed |
NCT01700608 -
Prospective Observational Study on Plerixafor After Chemotherapy
|
N/A | |
Completed |
NCT00606437 -
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
|
Phase 1 | |
Recruiting |
NCT05528887 -
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
|
Phase 1 | |
Recruiting |
NCT05625971 -
Non-invasive MRD Assessment in Multiple Myeloma
|
||
Active, not recruiting |
NCT02931942 -
Changing Over Time of Ascorbic Acid After Chemotherapy
|
||
Active, not recruiting |
NCT05889221 -
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
|
N/A | |
Recruiting |
NCT03836690 -
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
|
Phase 1 | |
Active, not recruiting |
NCT02542657 -
Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma
|
Phase 1/Phase 2 | |
Completed |
NCT01279694 -
Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)
|
Phase 1/Phase 2 | |
Completed |
NCT01191060 -
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
|
Phase 3 | |
Terminated |
NCT00983346 -
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
|
Phase 2 | |
Completed |
NCT00344422 -
Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
|
Phase 3 |